Bravis 10 mg/ml kapi za oko, suspenzija 克罗地亚 - 克罗地亚文 - HALMED (Agencija za lijekove i medicinske proizvode)

bravis 10 mg/ml kapi za oko, suspenzija

zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - brinzolamid - kapi za oko, suspenzija - 10 mg/ml - urbroj: jedan ml suspenzije sadrži 10 mg brinzolamida

Byooviz 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ximluci 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Vabysmo 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

vabysmo

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Ranivisio 欧盟 - 克罗地亚文 - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

LUCENTIS 10mg/ml Rastvor za injekciju 黑山共和国 - 克罗地亚文 - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

lucentis 10mg/ml rastvor za injekciju

"novartis pharma services ag" dio stranog druŠtva podgorica - ranibizumab - rastvor za injekciju - 10mg/ml

MEDICINSKI KISEONIK 100%v/v Medicinski gas, komprimovani 黑山共和国 - 克罗地亚文 - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

medicinski kiseonik 100%v/v medicinski gas, komprimovani

"messer tehnogas" ad beograd - "fabrika petrovac" - petrovac - kiseonik - medicinski gas, komprimovani - 100%v/v